Heron Therapeutics annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Heron Therapeutics's operating margin was −1.64% for fiscal 2025.
View full Heron Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1.64% | +6.35 pp |
| 2024 | 2024-12-31 | −7.99% | +79.08 pp |
| 2023 | 2023-12-31 | −87.07% | +75.14 pp |
| 2022 | 2022-12-31 | −162.21% | +90.06 pp |
| 2021 | 2021-12-31 | −252.27% | +5.14 pp |
| 2020 | 2020-12-31 | −257.41% | −113.07 pp |
| 2019 | 2019-12-31 | −144.34% | +93.08 pp |
| 2018 | 2018-12-31 | −237.42% | +394.94 pp |
| 2017 | 2017-12-31 | −632.36% | +12730.82 pp |
| 2016 | 2016-12-31 | −13,363.17% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5.43% | −1.03 pp |
| Q1 2026 | 2026-03-31 | −13.73% | −21.83 pp |
| Q4 2025 | 2025-12-31 | 0.09% | −10.14 pp |
| Q3 2025 | 2025-09-30 | −10.71% | +2.88 pp |
| Q2 2025 | 2025-06-30 | −4.40% | +13.49 pp |
| Q1 2025 | 2025-03-31 | 8.11% | +21.95 pp |
| Q4 2024 | 2024-12-31 | 10.23% | +40.09 pp |
| Q3 2024 | 2024-09-30 | −13.59% | +65.72 pp |
| Q2 2024 | 2024-06-30 | −17.89% | +115.61 pp |
| Q1 2024 | 2024-03-31 | −13.84% | +97.80 pp |
| Q4 2023 | 2023-12-31 | −29.85% | +37.93 pp |
| Q3 2023 | 2023-09-30 | −79.31% | +78.40 pp |
| Q2 2023 | 2023-06-30 | −133.50% | +45.64 pp |
| Q1 2023 | 2023-03-31 | −111.64% | +156.61 pp |
| Q4 2022 | 2022-12-31 | −67.79% | +191.41 pp |
| Q3 2022 | 2022-09-30 | −157.71% | +64.89 pp |
| Q2 2022 | 2022-06-30 | −179.15% | +90.29 pp |
| Q1 2022 | 2022-03-31 | −268.25% | −7.91 pp |
| Q4 2021 | 2021-12-31 | −259.20% | +38.28 pp |
| Q3 2021 | 2021-09-30 | −222.59% | +69.84 pp |
| Q2 2021 | 2021-06-30 | −269.43% | −23.50 pp |
| Q1 2021 | 2021-03-31 | −260.34% | −52.72 pp |
| Q4 2020 | 2020-12-31 | −297.48% | −128.28 pp |
| Q3 2020 | 2020-09-30 | −292.43% | −210.66 pp |
| Q2 2020 | 2020-06-30 | −245.94% | −104.69 pp |
| Q1 2020 | 2020-03-31 | −207.61% | −2.88 pp |
| Q4 2019 | 2019-12-31 | −169.20% | +8.70 pp |
| Q3 2019 | 2019-09-30 | −81.77% | +129.39 pp |
| Q2 2019 | 2019-06-30 | −141.24% | +83.64 pp |
| Q1 2019 | 2019-03-31 | −204.73% | +244.73 pp |
| Q4 2018 | 2018-12-31 | −177.90% | +437.74 pp |
| Q3 2018 | 2018-09-30 | −211.16% | +270.81 pp |
| Q2 2018 | 2018-06-30 | −224.88% | +269.30 pp |
| Q1 2018 | 2018-03-31 | −449.47% | +907.88 pp |
| Q4 2017 | 2017-12-31 | −615.64% | — |
| Q3 2017 | 2017-09-30 | −481.96% | — |
| Q2 2017 | 2017-06-30 | −494.18% | — |
| Q1 2017 | 2017-03-31 | −1,357.35% | — |
Over the last five reported fiscal years, Heron Therapeutics's operating margin increased from −257.41% to −1.64%, a change of +255.77 percentage points. The latest reported quarter, Q2 2026, shows −5.43%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heron Therapeutics filings at SEC.gov ↗